TOTUM-070

DIETARY_SUPPLEMENT3 trials

Sponsors

Valbiotis

Conditions

AtherosclerosisCardio-metabolic RiskCardiovascular Risk FactorDyslipidemiasHypercholesterolemiaOverweight and Obesity

Unknown Phase

Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects

CompletedNCT04760951

ValbiotisAtherosclerosis, Cardiovascular Risk Factor, Dyslipidemias +2

Start: 2021-02-17End: 2022-02-17Updated: 2022-03-29

Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk

TerminatedNCT05594979

ValbiotisAtherosclerosis, Cardio-metabolic Risk, Cardiovascular Risk Factor +2

Start: 2022-12-14End: 2023-09-27Updated: 2024-02-09

Effect of the Food Supplement TOTUM-070 on Lipid Metabolism

Active, not recruitingNCT06243484

ValbiotisHypercholesterolemia

Start: 2023-10-04End: 2025-04-30Updated: 2024-07-01

Related Papers

A polyphenol-rich active substance (TOTUM-070) lowers LDL-cholesterol in subjects with moderate hypercholesterolemia. The OLALIP study

European Journal of Preventive Cardiology2024-06-01